Disrupting drug development by establishing an Asia-centric commercial innovation platform
AUM’s goal is to take leading edge research and science and make it commercially viable.
Our competitive advantage and unique proposition is to create value for our partners, patients, payers and investors. AUM will apply its unique digital and precision medicine strategies to improve diagnosis, treatment, compliance and other aspects of patient engagement in cancer therapies.
Focusing on small molecules, AUM will in-license assets from academia and industry partners and aims to establish a pipeline targeting Asia prevalent tumour types.
AUM will focus on early-stage development of innovative medicines for the treatment of Asia-prevalent cancers and seek global partners to undertake late-stage clinical development and commercialisation.
Headquartered in Singapore, AUM is strategically positioned to work with leading research centres throughout Asia and have direct access to Asian patients.
The company secured seed financing in June 2018 and is reviewing initial development candidates for in-licensing with a therapeutic focus on potential new treatments for Asia-prevalent cancers.
AUM’s digitalisation approach has the potential to reduce the cost of clinical trials by 20%
Global market for oncology therapeutic medicines will grow to c. US$200 billion by 2022
Of 55 drugs approved in oncology globally in 2017, fewer than 20%1 are available in most pharmerging markets
1 IQVIA Oncology trend report 2018
Burden of cancer in Asia is projected to increase by 41% for incidence and 44% for mortality